EGFR and non-small cell lung carcinoma: A subgroup analysis of the IMpower150 trial showed that treatment with the PD-L1 inhibitor atezolizumab, bevacizumab, and chemotherapy (carboplatin and paclitaxel) improved survival outcomes in NSCLC patients who developed EGFR mutations after TKI treatment (19, 20).